Response to afatinib in patients with advanced NSCLC previously treated with reversible EGFR inhibitors in a mono-institutional experience.

Chiara Bennati,Maria Francesca Currà,Rita Chiari,Verena De Angelis,Vincenzo Minotti,Giulio Metro,Simona Duranti,Carmen Molica,Chiara Scafati,Luca Paglialunga,Lorenza Pistola,A. Flacco,Francesca Romana Tofanetti,Annamaria Siggillino,Elisa Baldelli,Vienna Ludovini,Lucio Crinò

Response to afatinib in patients with advanced NSCLC previously treated with reversible EGFR inhibitors in a mono-institutional experience.

2017

Chiara Bennati
Maria Francesca Currà
Rita Chiari
Verena De Angelis
Vincenzo Minotti
Giulio Metro
Simona Duranti
Carmen Molica
Chiara Scafati
Luca Paglialunga
Lorenza Pistola
A. Flacco
Francesca Romana Tofanetti
Annamaria Siggillino
Elisa Baldelli
Vienna Ludovini
Lucio Crinò

e18101 Background: All mutated non-small cell lung cancer (NSCLC) patients (pts) previously treated with an EGFR reversibile inhibitor, develop, soon or later, resistance. Afatinib is a potent irre...

Keywords:

EGFR inhibitors
Afatinib
Cell
Pathology
Cancer research
Lung cancer
Medicine
Internal medicine
in patient
Oncology
non small cell
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations